Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

e commercially available product. The safety data generated to date has shown UDB to be well tolerated with no significant adverse events reported.

MAP0004 Phase 3 Program

MAP Pharmaceuticals expects to complete enrollment in its initial Phase 3 clinical trial for the acute treatment of migraine by the end of January 2009. The Phase 3 multi-center, randomized, double-blind, placebo controlled trial in approximately 850 migraine sufferers is evaluating MAP0004 as a potential acute treatment for migraine. Patients enrolled in the trial will be evaluated for the treatment of a single migraine and will continue to be followed in a long-term safety trial. MAP Pharmaceuticals is conducting this first Phase 3 trial and the long-term safety trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, orally inhaled migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraine for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy- to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes with sustained relief to 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product cand
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Robotic cars attracted attention last decade with a 100-mile driverless ... put up by the U.S. government. The past ... microrobots, miniaturized mobile machines designed to perform specific tasks. And ... some think the time has come for a microrobotics challenge. ...
... CASTRES, France , July 2, 2010 Olivier ... Pierre Fabre,Group starting September 1, 2010 . , ... Until now, Olivier Bohuon , 51, ... such, he ran the,group,s entire pharmaceutical activities from Chicago ( $22 ...
... ... progenitors into specific T cell lineages to the activity of a single gene encoding a ... for the development of blood cells lineages. , ... (PRWeb UK) July 1, 2010 -- A research team in Japan has ...
Cached Biology Technology:Thermal-powered, insect-like robot crawls into microrobot contenders' ring 2Thermal-powered, insect-like robot crawls into microrobot contenders' ring 3Olivier Bohuon Joins Pierre Fabre 2The Last Checkpoint to T Cell Fate 2
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... Health (NIMH), part of the National Institutes of Health, ... social behavior in humans--one of the most important but ... reported in Nature Neuroscience, published online on July 10, ... volunteers to those with a genetic abnormality, Williams Syndrome, ...
... Academy of Sciences (CAS) and the Danish Committee of ... release of pig genomic sequences. The released sequence data ... different domestic pig breeds from Europe and China. The ... genome sequencing effort, the Sino-Danish Pig Genome Project, started ...
... truckers and college students pulling all-nighters, appears to do ... is one of several in a new study that ... the modulation of sleep, wake, and arousal states. , ... colleagues at The Neurosciences Institute in San Diego. , ...
Cached Biology News:Scientists uncover new clues about brain function in human behavior 2Scientists uncover new clues about brain function in human behavior 3‘Blue Brain?project explores thought at molecular level 2